3D Medicines Past Earnings Performance
Past criteria checks 0/6
3D Medicines has been growing earnings at an average annual rate of 18.2%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 31.4% per year.
Key information
18.2%
Earnings growth rate
65.0%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -31.4% |
| Return on equity | -62.9% |
| Net Margin | -92.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How 3D Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 489 | -450 | 450 | 359 |
| 31 Mar 24 | 562 | -487 | 523 | 392 |
| 31 Dec 23 | 635 | -525 | 596 | 425 |
| 30 Sep 23 | 674 | -710 | 605 | 377 |
| 30 Jun 23 | 713 | -894 | 614 | 329 |
| 31 Mar 23 | 640 | -959 | 557 | 340 |
| 31 Dec 22 | 567 | -1,024 | 501 | 351 |
| 31 Dec 21 | 60 | -1,434 | 194 | 371 |
Quality Earnings: 1244 is currently unprofitable.
Growing Profit Margin: 1244 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1244 is unprofitable, but has reduced losses over the past 5 years at a rate of 18.2% per year.
Accelerating Growth: Unable to compare 1244's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1244 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.4%).
Return on Equity
High ROE: 1244 has a negative Return on Equity (-62.93%), as it is currently unprofitable.